Schott Pharma, a pioneer in drug containment and delivery solutions, has announced that TPG, a leading global alternative asset management firm, has entered into a binding agreement to acquire a 35% stake in its joint venture Schott Poonawalla from Serum Institute of India (SII).
Schott Poonawalla is a joint venture of Schott Pharma and SII, part of the Cyrus Poonawalla Group and a global leader in vaccine manufacturing, dedicated to providing affordable vaccines worldwide. TPG Growth, TPG’s middle market and growth equity platform, is funding the investment, along with Novo Holdings as a co-investor. Following the transaction, SII will retain a minority stake in the company.
With deep healthcare investing experience and local expertise in India, having TPG join the partnership alongside Schott Pharma and Serum Institute of India represents a significant milestone in Schott Poonawalla’s growth, equipping the company with additional resources and strategic insight to support its long-term global ambitions.
Schott Poonawalla designs advanced drug containment and delivery solutions for pharmaceutical and biotechnology customers. The company’s portfolio features a large range of products including cartridges for auto-injector pens, prefillable syringes for a wide variety of biologics, vials, ampoules, as well as regulatory services for biotech and pharmaceutical companies, and Contract Development and Manufacturing Organisations (CDMOs).
The transaction is subject to customary closing conditions and is expected to close within the first half of 2025.
